Abstract: A safe, stabilized lyophilized preparation comprising parathyroid hormone (PTH) as an active ingredient and effective amounts of sugar and sodium chloride to provide a stable preparation of parathyroid hormone.

Abstract: A parathyroid hormone-containing emulsion for nasal administration, comprising parathyroid hormone as the active ingredient, at least, azacycloalkane derivative of the general formula [1]: ##STR1## wherein R is alkyl, m is an integer of 2-4, and n is an integer of 1-15, provided that R is alkyl of C.sub.5-11 in case where n is 1-3, as the absorption promotor, glycyrrhizic acid or its non-toxic salt, and a suitable amount of water.

Abstract: The present invention is to provide emulsion preparations for nasal administration containing calcitonins, which are safely and effectively administrated compared with the conventional calcitonin preparations. The emulsions are prepared by using a calcitonin as the active ingredient, an azacycloalkane derivative as the absorption promotor such as 1-[2-(decylthio)ethyl] azacyclopentan-2-one, and glycyrrhizic acid or its salt.

Abstract: A nasal administration powder composition containing a physiologically active peptide as an active ingredient can be efficiently absorbed through nasal mucosa by the addition of a water-soluble organic acid as an absorption promoter. This composition may further contain a diluent. The water-soluble organic acid used as absorption promoter includes, for example, at least one of succinic acid, tartaric acid, citric acid, fumaric acid, maleic acid, malonic acid, glutaric acid, adipic acid, malic acid, L-glutamic acid, L-aspartic acid, gluconic acid and glucuronic acid.

Abstract: 4"-deoxy-3"-demethoxy-3"-methylene-desmycosin derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen, acyl or substituted carbamoyl,R.sub.2 is ##STR2## R.sub.3 is hydrogen or a protective group for hydroxy, R.sub.4 is hydrogen, hydroxy or protected hydroxy, and Me is --CH.sub.3, and pharmaceutically acceptable salts thereof are produced.These novel derivatives have antibiotic properties superior to the known related antibiotics tylosin and desmycosin.

Abstract: 20-O-Acyl-19,20-enolmacrolide antibiotic derivatives represented by the following general formula (I): ##STR1##

Abstract: A compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are long-chain fatty acid residue, and Ns is nucleoside residue selected from the group consisting of 5-fluorouridine-5'-yl, 5-fluoro-2'-deoxyuridine-5'-yl-, bredinin-5'-yl, tubercidine-5'-yl-, neplanocin A-6'-yl-, 5-fluorocytidine-5'-yl-, arabinosylcytosine-5'-yl, arabinocyl-5-fluorocytosine-5'-yl-, arabinosyladenine-5'-yl- and arabinosylthymine-5 '-yl-, and pharmacologically acceptable salts thereof, having antitumor activity.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is lower alkyl, lower alkoxycarbonyl-lower alkyl, phenyl, phenyl substituted by one or more lower alkyl or halogen, phenyl-lower alkyl optionally substituted in its side chain by lower alkyl or lower alkoxycarbonyl, thienylmethyl or thiazolyl, R.sub.2 is hydrogen or lower alkyl, or ##STR2## constitutes a 3-7-membered nitrogen-containing heterocyclic ring in which R.sub.1 and R.sub.2 are connected, R.sub.3 is hydrogen or hydroxyl, and X is oxygen or sulfur, or a non-toxic salt thereof. These compounds have stronger antibacterial activity as compared with known clinically used macrolide antibiotics such as erythromycin, oleandomycin, josamycin and leucomycin, and also have strong antibacterial activity against all macrolide antibiotic-resistant strains such as macrolide-resistant A group strains (clinical isolates or erythromycin, oleandomycin and 16-membered macrolide antibiotic resistant strains).

Abstract: Antibiotic acmimycin of the formula ##STR1## is active against Gram positive and Gram negative bacteria. It is produced by culturing the microorganism Streptomyces sp. AC4559 FERM P-6445, and isolating the above compound from the cultured medium.

Abstract: Novel 23-demycinosyldesmycosin derivatives are disclosed of the formula ##STR1## wherein A is oxygen or sulfur, R.sub.1 is optionally substituted phenyl or ##STR2## group, in which R.sub.3 is optionally substituted phenyl and R.sub.4 and R.sub.5 are the same or different and are hydrogen, lower alkyl or optionally substituted phenyl, and R.sub.2 is hydrogen or hydroxyl. The compounds or non-toxic salts thereof are useful as antibiotics.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is optionally substituted phenyl, thienyl, 2-amino-4-thiazolyl or 2-chloroacetamido-4-thiazolyl; A is lower alkylene, lower alkenylene, or lower alkylene substituted by lower alkyl, amino, lower alkoxyimino or phenyl-Z-group wherein Z is a single bond or --S-- or --SO.sub.2 --, but when R.sub.1 is 2-amino-4-thiazolyl or 2-chloroacetamido-4-thiazolyl then A is lower alkylene substituted by lower alkoxyimino; R.sub.2 is hydrogen or hydroxyl; X is oxygen or sulfur and n=0 or 1, or a non-toxic salt thereof. These compounds have a stronger antibacterial activity against Gram positive bacteria as compared with known macrolide antibiotics such as erythromycin and tylosin, and also have an equivalent level of antibacterial activity against Gram negative bacteria as compared with that of erythromycin, and hence may be useful for clinical use. These compounds are also useful for feed additives and growth stimulants.

Abstract: Antibiotic saccharocins of the formula ##STR1## wherein R is hydrogen (saccharocin) or hydroxyl (3'-oxysaccharocin) are produced by culturing a microorganism belonging to the genus Saccharopolyspora, for example Saccharopolyspora sp. AC 3440 FERM-P No. 6238, in a conventional nutrient medium, and separating the thus-produced saccharocins from the cultured medium. The noval saccharocins exhibit anti-bacterial activity against Gram negative bacteria.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or hydroxy and at least one of R.sub.1 and R.sub.2 is hydrogen, or a pharmaceutically acceptable salt thereof, has strong antimicrobial and antibacterial activity..

Abstract: A compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or hydroxyl and at least one of R.sub.1 and R.sub.2 is hydrogen, or a pharmaceutically acceptable salt thereof, has antibacterial activity against Gram positive bacteria and against macrolide-resistant A group bacteria.

Abstract: Deformyltylosin derivatives of the formula ##STR1## wherein A is ##STR2## --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, R.sub.1 is hydrogen, lower alkanoyl or aryl-lower alkanoyl, X.sub.1 and X.sub.2 are hydrogen or are connected to form a valence bond, Y.sub.1 and Y.sub.2 are hydrogen or are connected to form a valence bond, Q.sub.1 is hydrogen or methyl, Q.sub.2 is hydrogen or ##STR3## R.sub.2 is hydrogen or lower alkanoyl, R is hydrogen or ##STR4## R.sub.3 is hydrogen or C.sub.2-5 alkanoyl, and R.sub.4 is hydrogen or C.sub.2-6 alkanoyl, and when R.sub.3 is not hydrogen, then R.sub.4 is not hydrogen, or a pharmaceutically acceptable salt thereof, have strong antibacterial activities as compared to the known antibiotic tylosin, and also have enhanced antibacterial activities against all macrolide antibiotic-resistant strains such as A, B and C group strains, and have higher blood levels as compared with tylosin.

Abstract: Derivatives of antibiotic tylosin of the formula ##STR1## wherein R.sub.1 is hydrogen or lower alkanoyl, A.sub.1 and A.sub.2 are groups of which one is R.sub.2 and the other is R.sub.3, and R.sub.2 and R.sub.3 are C.sub.2-6 alkanoyl, or a physiologically acceptable salt thereof, have enhanced antibacterial activity against macrolide antibiotic-resistant strains.

Abstract: 3"-acylated macrolide antibiotics of the formula ##STR1## wherein R.sub.1 is hydrogen or C.sub.2-3 alkanoyl, R.sub.2 is hydrogen or C.sub.2-4 alkanoyl, at least one of R.sub.1 and R.sub.2 being hydrogen, and one of R' and R" being R.sub.3 and the other R.sub.4, R.sub.3 being C.sub.2-6 alkanoyl and R.sub.4 being C.sub.2-5 alkanoyl, or a pharmaceutically acceptable salt thereof.